(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE) announced on Wednesday that it has agreed to sell a Rare Pediatric Disease Priority Review Voucher for $203 million.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.